Condition
Lung Fibrosis Interstitial
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (3)
Trial Status
Recruiting2
Not Yet Recruiting1
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07673237Not ApplicableNot Yet Recruiting
Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring
NCT07457463Not ApplicableRecruitingPrimary
Evaluation of the Pulmonary Fibrosis Learning and Self-management Programme (FILIP)
NCT06917196Recruiting
PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND POST-INFLAMMATORY FIBROSIS.
NCT06191367Not ApplicableUnknownPrimary
Effect of Aerobic Exercises Versus Incentive Spirometer Device on Post-covid Pulmonary Fibrosis Patients
Showing all 4 trials